Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.

@article{Kreitman2009RecombinantIF,
  title={Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.},
  author={Robert J. Kreitman},
  journal={Current pharmaceutical design},
  year={2009},
  volume={15 23},
  pages={
          2652-64
        }
}
Recombinant immunotoxins are proteins composed of fragments of monoclonal antibodies fused to truncated protein toxins. No agents of this class are approved yet for medical use, although a related molecule, denileukin diftitox, composed of interleukin-2 fused to truncated diphtheria toxin, is approved for relapsed/refractory cutaneous T-cell lymphoma. Recombinant immunotoxins which have been tested in patients with chemotherapy-pretreated hematologic malignancies include LMB-2 (anti-CD25), BL22… CONTINUE READING
17 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…